Wednesday, September 2, 2015

J&J Q3 sales rise 7 pct. led by its Remicade drug

The pharmaceutical and medical device company's net income fell 6 percent, but earnings excluding items beat analyst estimates.

J&J Q3 sales rise 7 pct. led by its Remicade drug


Johnson & Johnson reported Q3 sales rose 6.8 percent to $16 billion over last year's $14.98 billion. Net earnings were down 6.3 percent to $3.2 billion, or $1.15 per share, from $3.4 billion, or $1.23 per share.

Its top pharmaceutical sales driver was Remicade, a biologic developed by the Philadelphia region's own Centocor, which J&J acquired in 1999. Sales of Remicade, used to treat arthritis, Crohn's disease and psoriasis, rose to $1.41 billion in the third quarter, up from $1.23 billion for the same quarter last year.

Johnson & Johnson said sales of its U.S. over-the-counter medicines were "significantly impacted" by the halt of manufacturing at its McNeil Consumer Healthcare factory in Fort Washington in April 2010. The Food and Drug Administration documented many manufacturing and quality control problems at that plant, which made Tylenol, Motrin and other medicines.

For the third quarter, U.S. sales of its OTC/Nutritionals consumer segment were $332 million, down 24.2 percent from $438 million for the three months ended Sept. 30, 2010.

Still, as Reuters reports, J&J's results did beat Wall Street analyst forecasts by 3 cents per share.

In other local business news, retail chain A.C. Moore Arts & Crafts said that Sbar's Inc. has begun its previously announced tender offer to acquire all of A.C. Moore's shares for $1.60 per share. The Moorestown-based Sbar's is a large distributor of arts and crafts merchandise and intends to take private the 134-store A.C. Moore chain in a deal valued at $41 million.

Inquirer Columnist
We encourage respectful comments but reserve the right to delete anything that doesn't contribute to an engaging dialogue.
Help us moderate this thread by flagging comments that violate our guidelines.

Comment policy: comments are intended to be civil, friendly conversations. Please treat other participants with respect and in a way that you would want to be treated. You are responsible for what you say. And please, stay on topic. If you see an objectionable post, please report it to us using the "Report Abuse" option.

Please note that comments are monitored by staff. We reserve the right at all times to remove any information or materials that are unlawful, threatening, abusive, libelous, defamatory, obscene, vulgar, pornographic, profane, indecent or otherwise objectionable. Personal attacks, especially on other participants, are not permitted. We reserve the right to permanently block any user who violates these terms and conditions.

Additionally comments that are long, have multiple paragraph breaks, include code, or include hyperlinks may not be posted.

Read 0 comments
comments powered by Disqus
About this blog
Mike Armstrong blogs about Philadelphia corporations and business-related topics. Contact him at 215-854-2980. Reach Mike at

Mike Armstrong Inquirer Columnist
Also on
letter icon Newsletter